[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"CD47,,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Y. Shi<sup>1<\/sup>, J. Yang<sup>1<\/sup>, Y. Song<sup>2<\/sup>, K. Zhou<sup>2<\/sup>, Z. Li<sup>3<\/sup>, M. Zhang<sup>4<\/sup>, H. Jing<sup>5<\/sup>, Z. Wang<sup>6<\/sup>, L. Yu<sup>7<\/sup>, Q. Lu<sup>8<\/sup>, <b>F. Gan<\/b><sup>9<\/sup>, W. Tian<sup>8<\/sup>; <br\/><sup>1<\/sup>Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular , Beijing, China, <sup>2<\/sup>Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China, <sup>3<\/sup>Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, <sup>4<\/sup>Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, <sup>5<\/sup>Department of Hematology, Peking University Third Hospital, Beijing, China, <sup>6<\/sup>Department of Medical Oncology, Linyi Cancer Hospital, Linyi, China, <sup>7<\/sup>Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, <sup>8<\/sup>Immuneonco Biopharmaceuticals (Shanghai) Inc, Shanghai, China, <sup>9<\/sup>ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai, China","CSlideId":"","ControlKey":"f3c63338-9593-4314-bd9f-d5f216dc8260","ControlNumber":"9820","DisclosureBlock":"&nbsp;<b>Y. Shi, <\/b> None..<br><b>J. Yang, <\/b> None..<br><b>Y. Song, <\/b> None..<br><b>K. Zhou, <\/b> None..<br><b>Z. Li, <\/b> None..<br><b>M. Zhang, <\/b> None..<br><b>H. Jing, <\/b> None..<br><b>Z. Wang, <\/b> None..<br><b>L. Yu, <\/b> None.&nbsp;<br><b>Q. Lu, <\/b> <br><b>Immuneonco Biopharmaceuticals (Shanghai) Inc<\/b> Employment. <br><b>F. Gan, <\/b> <br><b>ImmuneOnco Biopharmaceuticals (Shanghai) Inc.<\/b> Employment. <br><b>W. Tian, <\/b> <br><b>Immuneonco Biopharmaceuticals (Shanghai) Inc<\/b> Employment.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11463","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT173","PresenterBiography":null,"PresenterDisplayName":"Frank Gan, PharmD","PresenterKey":"996fe941-4eab-402b-a8ed-8bc986ef3e32","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT173. Preliminary results from a phase I study of IMM0306 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Preliminary results from a phase I study of IMM0306 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Lymphoma: non-Hodgkin's lymphoma,Chronic lymphocytic leukemia,Antibody-drug conjugate (ADC),,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>P. Abrisqueta<\/b><sup>1<\/sup>, R. Marks<sup>2<\/sup>, I. Avivi<sup>3<\/sup>, M. Wermke<sup>4<\/sup>, F. Lim<sup>5<\/sup>, T. M. Kim<sup>6<\/sup>, A. C. Touzon<sup>1<\/sup>, K. Karihtala<sup>7<\/sup>, S. Makita<sup>8<\/sup>, L. Werner<sup>9<\/sup>, C. Tanaka<sup>10<\/sup>, A. Dang<sup>9<\/sup>, A. Chaudhury<sup>11<\/sup>, S. Rice<sup>12<\/sup>, R. Chowdhury<sup>9<\/sup>, D. Knee<sup>13<\/sup>, B. Gomezcarrillo<sup>14<\/sup>, E. Furutani<sup>9<\/sup>, K. Izutsu<sup>8<\/sup>, S. Leppä<sup>7<\/sup>; <br\/><sup>1<\/sup>Department of Hematology, University Hospital Vall d´Hebron, Barcelona, Spain, <sup>2<\/sup>Uniklinikum Freiburg Albert-Ludwigs-Uni, Freiburg, Germany, <sup>3<\/sup>Tel Aviv Sourasky Medical Center-Ichilov, Tel Aviv, Israel, <sup>4<\/sup>Universitaetsklinikum Dresden, Dresden, Germany, <sup>5<\/sup>Singapore General Hospital, Singapore, Singapore, <sup>6<\/sup>Seoul National University Hospital, Seoul, Korea, Republic of, <sup>7<\/sup>Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland, <sup>8<\/sup>Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, <sup>9<\/sup>Biomedical Research Novartis, Cambridge, MA, <sup>10<\/sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, <sup>11<\/sup>Novartis Pharmaceutical Corporation, Cambridge, MA, <sup>12<\/sup>MCPHS University, Boston, MA, <sup>13<\/sup>Biomedical Research Novartis, San Diego, CA, <sup>14<\/sup>Biomedical Research Novartis, Emeryville, CA","CSlideId":"","ControlKey":"53725b5c-92d0-43ef-8fad-6e8eb41ff34a","ControlNumber":"9548","DisclosureBlock":"<b>&nbsp;P. Abrisqueta, <\/b> <br><b>Roche<\/b> Other, Consulting\/advisory and Honoraria.. <br><b>Genmab<\/b> Other, Consulting\/advisory and Honoraria.. <br><b>Janssen<\/b> Other, Consulting\/advisory and Honoraria.. <br><b>BMS<\/b> Other, Consulting\/advisory and Honoraria.. <br><b>AbbVie<\/b> Other, Consulting\/advisory and Honoraria.. <br><b>AstraZeneca<\/b> Other, Consulting\/advisory and Honoraria.. <br><b>BeiGene<\/b> Other, Consulting\/advisory.. <br><b>Gilead<\/b> Other, Honoraria.. <br><b>Incyte<\/b> Other, Honoraria..<br><b>R. Marks, <\/b> None..<br><b>I. Avivi, <\/b> None..<br><b>M. Wermke, <\/b> None..<br><b>F. Lim, <\/b> None.&nbsp;<br><b>T. M. Kim, <\/b> <br><b>Amgen<\/b> Other, Consulting or advisory roles outside this work.. <br><b>AstraZeneca\/MedImmune<\/b> Other, Consulting or advisory roles outside this work.. <br><b>Boryung<\/b> Other, Consulting or advisory roles outside this work.. <br><b>Daiichi-Sankyo<\/b> Other, Consulting or advisory roles outside this work.. <br><b>HK inno. N<\/b> Other, Consulting or advisory roles outside this work.. <br><b>IMBDx. Inc.<\/b> Other, Consulting or advisory roles outside this work.. <br><b>Janssen<\/b> Other, Consulting or advisory roles outside this work.. <br><b>MSD<\/b> Other, Consulting or advisory roles outside this work.. <br><b>Novartis<\/b> Other, Consulting or advisory roles outside this work.. <br><b>Regeneron<\/b> Other, Consulting or advisory roles outside this work.. <br><b>Roche\/Genentech<\/b> Other, Consulting or advisory roles outside this work.. <br><b>Samsung Bioepis<\/b> Other, Consulting or advisory roles outside this work.. <br><b>Takeda<\/b> Other, Consulting or advisory roles outside this work.. <br><b>Yuhan<\/b> Other, Consulting or advisory roles outside this work.&nbsp;<br><b>A. C. Touzon, <\/b> <br><b>Janssen<\/b> Other, Consulting and Honoraria.. <br><b>AstraZeneca<\/b> Other, Consulting and Honoraria.. <br><b>BeiGene<\/b> Other, Honoraria.. <br><b>AbbVie<\/b> Other, Honoraria..<br><b>K. Karihtala, <\/b> None.&nbsp;<br><b>S. Makita, <\/b> <br><b>Abbvie<\/b> Other, Honoraria.. <br><b>Celgene\/BMS<\/b> Other, Honoraria.. <br><b>Chugai<\/b> Other, Honoraria.. <br><b>CSL Behring<\/b> Other, Honoraria.. <br><b>Daiichi-Sankyo<\/b> Other, Honoraria.. <br><b>Eisai<\/b> Other, Honoraria.. <br><b>Gilead<\/b> Other, Honoraria.. <br><b>Genmab<\/b> Other, Honoraria.. <br><b>Novartis<\/b> Other, Honoraria.. <br><b>Takeda<\/b> Other, Honoraria.&nbsp;<br><b>L. Werner, <\/b> <br><b>Novartis<\/b> Employment. <br><b>C. Tanaka, <\/b> <br><b>Novartis<\/b> Employment, Other, Owns Novartis shares.&nbsp;<br><b>A. Dang, <\/b> <br><b>Novartis<\/b> Employment, Other, Owns Novartis shares.&nbsp;<br><b>A. Chaudhury, <\/b> <br><b>Novartis<\/b> Employment, Other, Owns Novartis shares..<br><b>S. Rice, <\/b> None.&nbsp;<br><b>R. Chowdhury, <\/b> <br><b>Novartis<\/b> Employment. <br><b>D. Knee, <\/b> <br><b>Novartis<\/b> Employment, Other, Owns Novartis shares.&nbsp;<br><b>B. Gomezcarrillo, <\/b> <br><b>Novartis<\/b> Employment, Other, Owns Novartis shares.&nbsp;<br><b>E. Furutani, <\/b> <br><b>Novartis<\/b> Employment. <br><b>K. Izutsu, <\/b> <br><b>MSD<\/b> Grant\/Contract, Other, Consulting fees, Payment or honoraria for lectures, presentations, speakers bureaus. <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Consulting fees, Payment or honoraria for lectures, presentations, speakers bureaus. <br><b>Abbvie<\/b> Grant\/Contract, Other, Consulting fees, Payment or honoraria for lectures, presentations, speakers bureaus. <br><b>Eisai<\/b> Grant\/Contract, Other, Payment or honoraria for lectures, presentations, speakers bureaus. <br><b>Incyte<\/b> Grant\/Contract. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract, Other, Consulting fees, Payment or honoraria for lectures, presentations, speakers bureaus. <br><b>Novartis<\/b> Grant\/Contract, Other, Payment or honoraria for lectures, presentations, speakers bureaus. <br><b>Pfizer<\/b> Grant\/Contract, Other, Payment or honoraria for lectures, presentations, speakers bureaus. <br><b>Janssen<\/b> Grant\/Contract, Other, Payment or honoraria for lectures, presentations, speakers bureaus. <br><b>Yakult<\/b> Grant\/Contract. <br><b>Kyowa Kirin<\/b> Grant\/Contract, Other, Consulting fees, Payment or honoraria for lectures, presentations, speakers bureaus. <br><b>Ono Pharmaceutical<\/b> Grant\/Contract, Other, Consulting fees, Payment or honoraria for lectures, presentations, speakers bureaus. <br><b>Daiichi Sankyo<\/b> Grant\/Contract, Other, Payment or honoraria for lectures, presentations, speakers bureaus. <br><b>LOXO Oncology (Eli Lilly)<\/b> Grant\/Contract, Other, Payment or honoraria for lectures, presentations, speakers bureaus. <br><b>Zenyaku<\/b> Other, Consulting fees. <br><b>Nihon Shinyaku<\/b> Other, Consulting fees. <br><b>Genmab<\/b> Other, Consulting fees. <br><b>Mitsubishi Tanabe Pharma\u0009\u0009<\/b> Other, Consulting fees. <br><b>Nihon Kayaku<\/b> Other, Consulting fees. <br><b>Takeda<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus. <br><b>S. Leppä, <\/b> <br><b>Abbvie<\/b> Other, Consultancy. <br><b>Beigene<\/b> Other, Consultancy. <br><b>Gilead<\/b> Other, Consultancy and Honoraria.. <br><b>Incyte<\/b> Other, Consultancy and Honoraria.. <br><b>Novartis<\/b> Other, Consultancy, Research Funding and Honoraria.. <br><b>Roche<\/b> Other, Consultancy and Research Funding.. <br><b>Sobi<\/b> Other, Consultancy. <br><b>Bayer<\/b> Other, Research Funding.. <br><b>Celgene<\/b> Other, Research Funding.. <br><b>Genmab<\/b> Other, Research Funding.. <br><b>Hutchmed<\/b> Other, Research Funding.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11464","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT174","PresenterBiography":null,"PresenterDisplayName":"Pau Abrisqueta, MD, PhD","PresenterKey":"ab3fdde8-d9b9-4f3c-9a63-3b977035ff3a","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT174. A phase 1 study of JBH492, an anti C-C chemokine receptor 7 antibody-drug conjugate (anti-CCR7 ADC), assessing safety and efficacy in lymphoid malignancies<b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 1 study of JBH492, an anti C-C chemokine receptor 7 antibody-drug conjugate (anti-CCR7 ADC), assessing safety and efficacy in lymphoid malignancies<b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Tumor infiltrating lymphocytes,Melanoma\/skin cancers,Immuno-oncology,Adoptive cell therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>R. N. Amaria<\/b><sup>1<\/sup>, J. L. McQuade<sup>1<\/sup>, M. A. Davies<sup>1<\/sup>, I. C. Glitza Oliva<sup>1<\/sup>, S. Jose<sup>1<\/sup>, E. N. K. Cressman<sup>1<\/sup>, A. L. Clausell<sup>1<\/sup>, R. Bassett<sup>1<\/sup>, S. Patel<sup>1<\/sup>, A. Diab<sup>1<\/sup>, H. A. Tawbi<sup>1<\/sup>, M. K. Wong<sup>1<\/sup>, A. P. Ikeguchi<sup>1<\/sup>, M. Jagasia<sup>2<\/sup>, G. Ramsingh<sup>2<\/sup>, P. Prabhakar<sup>2<\/sup>, R. Duan<sup>2<\/sup>, P. Hari<sup>2<\/sup>; <br\/><sup>1<\/sup>MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>Obsidian Therapeutics, Inc., Cambridge, MA","CSlideId":"","ControlKey":"5467b1d3-2b9b-4adb-8b18-72c0b454e24e","ControlNumber":"9944","DisclosureBlock":"<b>&nbsp;R. N. Amaria, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Grant\/Contract, Other, Medical writing support; grant for OBX-115 FIH protocol paid to institution; Advisory Board. <br><b>J. L. McQuade, <\/b> <br><b>Merck<\/b> Other, Consulting. <br><b>Bristol Myers Squibb<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Roche<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>M. A. Davies, <\/b> <br><b>Pfizer, Lead Pharma, ABM Therapeutics<\/b> Grant\/Contract. <br><b>Roche Genentech, Novartis, Pfizer, ABM Therapeutics, Bristol Myers Squibb, Merck, Iovance, Eisai<\/b> Other, Consulting. <br><b>I. C. Glitza Oliva, <\/b> <br><b>Bristol Myers Squibb, Pfizer, Merck<\/b> Grant\/Contract. <br><b>Pfizer, Midatech, Novartis<\/b> Other, Consulting. <br><b>Pfizer, Novartis<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events.<br><b>S. Jose, <\/b> None..<br><b>E. N. K. Cressman, <\/b> None..<br><b>A. L. Clausell, <\/b> None..<br><b>R. Bassett, <\/b> None.&nbsp;<br><b>S. Patel, <\/b> <br><b>BMS, Foghorn Therapeutics, Ideaya, InxMed, Lyvgen Biopharma, Novartis, Provectus Biopharmaceuticals, Seagen, Syntrix Bio, TriSalus Life Sciences<\/b> Grant\/Contract. <br><b>Delcath, Immunocore<\/b> Other, Consulting. <br><b>Bristol Myers Squibb, Merck<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Provectus Biopharmaceuticals, Merck, Bristol Myers Squibb, TriSalus Life Sciences<\/b> Travel. <br><b>Bristol Myers Squibb, Cardinal Health, Castle Biosciences, Delcath, Ideaya, Immatics, Immunocore, MSD, Novartis, OncoSec, Pfizer, Replimune, TriSalus Life Sciences<\/b> Other, Participation on a Data Safety Monitoring Board or Advisory Board. <br><b>BMS, Foghorn Therapeutics, Ideaya, InxMed, Lyvgen Biopharma, Novartis, Provectus Biopharmaceuticals, Seagen, Syntrix Bio, TriSalus Life Sciences<\/b> Other, Receipt of equipment, materials, drugs, medical writing, gifts or other services.<br><b>A. Diab, <\/b> None.&nbsp;<br><b>H. A. Tawbi, <\/b> <br><b>Bristol Myers Squibb, Novartis, Merck, Genentech, GlaxoSmithKline, Eisai, Dragonfly Therapeutics<\/b> Grant\/Contract. <br><b>Bristol Myers Squibb, Genentech, Novartis, Merck, Karyopharm, Iovance, Eisai, Jazz Pharmaceuticals, Medicenna, Pfizer<\/b> Other, Consulting.<br><b>M. K. Wong, <\/b> None..<br><b>A. P. Ikeguchi, <\/b> None.&nbsp;<br><b>M. Jagasia, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option, Travel. <br><b>G. Ramsingh, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option, Travel. <br><b>P. Prabhakar, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option, Travel. <br><b>R. Duan, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>P. Hari, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option, Travel.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11466","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT176","PresenterBiography":null,"PresenterDisplayName":"Rodabe Amaria, TX","PresenterKey":"51fbfeca-f1f6-483a-b8b1-6f179e7a68da","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT176. OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy induced deepening and durable responses without interleukin 2 (IL2) in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy induced deepening and durable responses without interleukin 2 (IL2) in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"BRAF,Targeted therapy,Phase I,Novel clinical trial design,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"R. Yaeger<sup>1<\/sup>, <b>M. McKean<\/b><sup>2<\/sup>, R. Haq<sup>3<\/sup>, J. T. Beck<sup>4<\/sup>, M. H. Taylor<sup>5<\/sup>, J. Cohen<sup>6<\/sup>, D. Bowles<sup>7<\/sup>, S. M. Gadgeel<sup>8<\/sup>, C. Mihalcioiu<sup>9<\/sup>, K. P. Papadopoulos<sup>10<\/sup>, E. L. Diamond<sup>1<\/sup>, K. B. Sturtz<sup>11<\/sup>, G. Feng<sup>12<\/sup>, S. K. Drescher<sup>11<\/sup>, M. B. Reddy<sup>11<\/sup>, B. Sengupta<sup>11<\/sup>, A. K. Maity<sup>12<\/sup>, S. A. Brown<sup>11<\/sup>, A. Singh<sup>11<\/sup>, E. N. Brown<sup>11<\/sup>, B. R. Baer<sup>11<\/sup>, J. Wong<sup>11<\/sup>, T.-C. Mou<sup>11<\/sup>, W. I. Wu<sup>11<\/sup>, D. Kahn<sup>11<\/sup>, S. Gadal<sup>1<\/sup>, N. Rosen<sup>1<\/sup>, J. J. Gaudino<sup>11<\/sup>, P. A. Lee<sup>11<\/sup>, D. P. Hartley<sup>11<\/sup>, S. M. Rothenberg<sup>11<\/sup>; <br\/><sup>1<\/sup>Memorial Sloan Kettering Cancer Center, New York, NY, <sup>2<\/sup>Sarah Cannon Research Institute, Nashville, TN, <sup>3<\/sup>Dana-Farber Cancer Institute, Boston, MA, <sup>4<\/sup>Highlands Oncology, Fayetville, AR, <sup>5<\/sup>Providence Portland Medical Center, Portland, OR, OR, <sup>6<\/sup>Hadassah Medical Center, Jerusalem, Israel, <sup>7<\/sup>University of Colorado Hospital, Aurora, CO, <sup>8<\/sup>Henry Ford Health System, Detroit, MI, <sup>9<\/sup>McGill University Health Centre, Montreal, AB, Canada, <sup>10<\/sup>South Texas Accelerated Research Therapeutics, San Antonio, TX, <sup>11<\/sup>Pfizer-Boulder Research and Development, Boulder, CO, <sup>12<\/sup>Pfizer Ealy Clinical Development, Cambridge, MA","CSlideId":"","ControlKey":"81ba6917-24af-4d42-8b6f-f6774415a61e","ControlNumber":"10283","DisclosureBlock":"&nbsp;<b>R. Yaeger, <\/b> None..<br><b>M. McKean, <\/b> None..<br><b>R. Haq, <\/b> None..<br><b>J. T. Beck, <\/b> None..<br><b>M. H. Taylor, <\/b> None..<br><b>J. Cohen, <\/b> None..<br><b>D. Bowles, <\/b> None..<br><b>S. M. Gadgeel, <\/b> None..<br><b>C. Mihalcioiu, <\/b> None..<br><b>K. P. Papadopoulos, <\/b> None..<br><b>E. L. Diamond, <\/b> None.&nbsp;<br><b>K. B. Sturtz, <\/b> <br><b>Pfizer<\/b> Employment. <br><b>G. Feng, <\/b> <br><b>Pfizer<\/b> Employment. <br><b>S. K. Drescher, <\/b> <br><b>Pfizer<\/b> Employment. <br><b>M. B. Reddy, <\/b> <br><b>Pfizer<\/b> Employment. <br><b>B. Sengupta, <\/b> <br><b>Pfizer<\/b> Employment. <br><b>A. K. Maity, <\/b> <br><b>Pfizer<\/b> Employment. <br><b>S. A. Brown, <\/b> <br><b>Pfizer<\/b> Employment. <br><b>A. Singh, <\/b> <br><b>Pfizer<\/b> Employment. <br><b>E. N. Brown, <\/b> <br><b>Pfizer<\/b> Employment. <br><b>B. R. Baer, <\/b> <br><b>Pfizer<\/b> Employment. <br><b>J. Wong, <\/b> <br><b>Pfizer<\/b> Employment. <br><b>T. Mou, <\/b> <br><b>Pfizer<\/b> Employment. <br><b>W. I. Wu, <\/b> <br><b>Pfizer<\/b> Employment. <br><b>D. Kahn, <\/b> <br><b>Pfizer<\/b> Employment.<br><b>S. Gadal, <\/b> None..<br><b>N. Rosen, <\/b> None.&nbsp;<br><b>J. J. Gaudino, <\/b> <br><b>Pfizer<\/b> Employment. <br><b>P. A. Lee, <\/b> <br><b>Pfizer<\/b> Employment. <br><b>D. P. Hartley, <\/b> <br><b>Pfizer<\/b> Employment. <br><b>S. M. Rothenberg, <\/b> <br><b>Pfizer<\/b> Employment.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11468","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT178","PresenterBiography":null,"PresenterDisplayName":"Meredith McKean, MD","PresenterKey":"d8b53c3e-044e-478a-b927-05391b2d5015","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT178. Phase 1 trial of PF-07799933 (ARRY-440), a next-generation BRAF inhibitor, for BRAF-mutant cancers","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 1 trial of PF-07799933 (ARRY-440), a next-generation BRAF inhibitor, for BRAF-mutant cancers","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Phase I,JSKN003,bispecific HER2-directed ADC,solid tumor,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Claire Beecroft<\/b><sup>1<\/sup>, Bo Gao<sup>2<\/sup>, John Park<sup>3<\/sup>, Kate Wilkinson<sup>4<\/sup>, Karl Zhang<sup>5<\/sup>, Xiangyun Yan<sup>5<\/sup>, Yuan Lv<sup>6<\/sup><br><br\/><sup>1<\/sup>Hollywood Private Hospital, Perth, Australia,<sup>2<\/sup>Blacktown and Westmead Hospital, Sydney, Australia,<sup>3<\/sup>Macquarie University Hospital, Sydney, Australia,<sup>4<\/sup>Liverpool Hospital, Liverpool, Australia,<sup>5<\/sup>Alphamab Oncology, Suzhou, China,<sup>6<\/sup>Alphamabonc.com, Suzhou, China","CSlideId":"","ControlKey":"3240af2c-3dc9-45be-8052-32a2cc091d97","ControlNumber":"10905","DisclosureBlock":"&nbsp;<b>C. Beecroft, <\/b> None..<br><b>B. Gao, <\/b> None..<br><b>J. Park, <\/b> None..<br><b>K. Wilkinson, <\/b> None..<br><b>K. Zhang, <\/b> None..<br><b>X. Yan, <\/b> None..<br><b>Y. Lv, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11469","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT179","PresenterBiography":null,"PresenterDisplayName":"Ping Zhang, PhD","PresenterKey":"228f3d75-908e-45d8-9fa7-e9598c9616f9","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT179. Safety and efficacy of JSKN003 in patients with advanced\/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Safety and efficacy of JSKN003 in patients with advanced\/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"CAR T cells,Acute lymphoblastic leukemia,interleukin-21,PD-1,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Y. Jing<sup>1<\/sup>, <b>Y. Li<\/b><sup>2<\/sup>, L. Dou<sup>1<\/sup>, S. Zhang<sup>3<\/sup>, R. Tian<sup>2<\/sup>, G. Wang<sup>3<\/sup>, X. Cheng<sup>3<\/sup>, J. Zhao<sup>2<\/sup>, H. Li<sup>3<\/sup>, Y. An<sup>2<\/sup>, N. Yang<sup>3<\/sup>, S. Wang<sup>2<\/sup>; <br\/><sup>1<\/sup>Chinese People's Liberation Army General Hospital, Beijing, China, <sup>2<\/sup>Institute of Biophysics, Chinese Academy of Sciences, Beijing, China, <sup>3<\/sup>CD(Suzhou)Biopharma Co.,Ltd., Suzhou, China","CSlideId":"","ControlKey":"8f512d39-075c-4211-85f8-541ae056e4cf","ControlNumber":"10538","DisclosureBlock":"&nbsp;<b>Y. Jing, <\/b> None..<br><b>Y. Li, <\/b> None..<br><b>L. Dou, <\/b> None..<br><b>S. Zhang, <\/b> None..<br><b>R. Tian, <\/b> None..<br><b>G. Wang, <\/b> None..<br><b>X. Cheng, <\/b> None..<br><b>J. Zhao, <\/b> None..<br><b>H. Li, <\/b> None..<br><b>Y. An, <\/b> None..<br><b>N. Yang, <\/b> None..<br><b>S. Wang, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11470","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT180","PresenterBiography":null,"PresenterDisplayName":"Ying Li, PhD","PresenterKey":"bc6f43ca-0c29-4786-b191-c9ad95311535","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT180. Phase I clinical trial of CD19CAR -T cells secreting PD-1-targeting IL-21 in advanced relapsed\/refractory acute lymphoblastic leukemia","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase I clinical trial of CD19CAR -T cells secreting PD-1-targeting IL-21 in advanced relapsed\/refractory acute lymphoblastic leukemia","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Anticancer therapy,VISTA,Immune checkpoint regulator,Solid tumors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>C. Gomez-Roca<\/b><sup>1<\/sup>, S. Champiat<sup>2<\/sup>, P. Cassier<sup>3<\/sup>, D. Jegou<sup>4<\/sup>, M. Primard<sup>4<\/sup>, A. Pétain<sup>4<\/sup>, G. Gueguen-Dorbes<sup>4<\/sup>, C. Fabre<sup>4<\/sup>, I. Melero<sup>5<\/sup>, A. Marabelle<sup>2<\/sup>; <br\/><sup>1<\/sup>Clinical Research & Early Phase Unit Medical Oncology Department, Oncopole Claudius Regaud Institut Universitaire du Cancer de Toulouse, Toulouse, France, <sup>2<\/sup>Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France, <sup>3<\/sup>Medical Oncology, Centre Léon Bérard, Lyon, France, <sup>4<\/sup>R&D Medical Care, Pierre Fabre Laboratories, Toulouse, France, <sup>5<\/sup>Immunology and Oncology, Clínica Universidad de Navarra, Pamplona, Spain","CSlideId":"","ControlKey":"0ede262f-4d01-48ba-8a54-b33c43e81170","ControlNumber":"9528","DisclosureBlock":"<b>&nbsp;C. Gomez-Roca, <\/b> <br><b>Bristol Myers Squibb<\/b> Honoraria, Consulting or Advisory Role,Research Funding (institution). <br><b>Foundation Medicine<\/b> Honoraria. <br><b>Genentech\/Roche<\/b> Travel, Honoraria, Research Funding (Institution). <br><b>Pierre Fabre<\/b> Travel, Honoraria. <br><b>Eisai<\/b> Honoraria. <br><b>Macomics<\/b> Honoraria. <br><b>Ellipses Pharma<\/b> Honoraria. <br><b>Amgen<\/b> Research Funding (Institution). <br><b>MSD Oncology<\/b> Travel. <br><b>S. Champiat, <\/b> <br><b>Amgen<\/b> Travel, Honoraria, Consulting or Advisory Role. <br><b>AstraZeneca<\/b> Travel, Honoraria, Consulting or Advisory Role. <br><b>Bristol Myers Squibb<\/b> Travel, Honoraria. <br><b>MSD<\/b> Honoraria. <br><b>Novartis<\/b> Honoraria. <br><b>Roche<\/b> Travel, Honoraria. <br><b>Fresenius Kabi<\/b> Honoraria. <br><b>Eisai Europe<\/b> Honoraria. <br><b>Genmab<\/b> Honoraria, Consulting or Advisory role. <br><b>Janssen<\/b> Honoraria. <br><b>Merck KGaA, Merck Serono<\/b> Honoraria. <br><b>Pierre Fabre Laboratories<\/b> Consulting or Advisory role. <br><b>Alderaan Biotech, Avacta Life Sciences, Celanese, Domain Therapeutics, Ellipses Pharma, Immunicom, Nanobiotix, Oncovita, Seattle Genetics, Tatum Bioscience, Tollys SAS, UltraHuman8, NextCure<\/b> Consulting or Advisory role. <br><b>P. Cassier, <\/b> <br><b>Amgen<\/b> Grant\/Contract. <br><b>EMD Serono<\/b> Grant\/Contract. <br><b>D. Jegou, <\/b> <br><b>Pierre Fabre Laboratories<\/b> Employment. <br><b>M. Primard, <\/b> <br><b>Pierre Fabre Laboratories<\/b> Employment. <br><b>A. Pétain, <\/b> <br><b>Pierre Fabre Laboratories<\/b> Employment. <br><b>G. Gueguen-Dorbes, <\/b> <br><b>Pierre Fabre Laboratories<\/b> Employment. <br><b>C. Fabre, <\/b> <br><b>Pierre Fabre Laboratories<\/b> Employment. <br><b>I. Melero, <\/b> <br><b>Bristol Myers Squibb<\/b> Travel, Consulting or Advisory Role, Research Funding. <br><b>Bayer<\/b> Consulting or Advisory Role. <br><b>Tusk Therapeutics<\/b> Consulting or Advisory Role. <br><b>MSD<\/b> Travel, Consulting or Advisory Role. <br><b>Roche\/Genentech<\/b> Travel, Consulting or Advisory Role, Research Funding. <br><b>F-star, Genmab, EMD Serono, Lilly, AZ\/MedImmune, Pieris Pharma, Numab, Noxxon Pharma, Servier, CRISPR therapeutics, Boston Pharma, Monopteros Therapeutics, Moderna Therapeutics, CatalYm, Gossamer Bio<\/b> Consulting or Advisory Role. <br><b>Incyte<\/b> Travel. <br><b>Alligator Bioscience<\/b> Research Funding. <br><b>Bioncotech<\/b> Research Funding. <br><b>A. Marabelle, <\/b> <br><b>Shattuck Labs, Centessa Pharmaceuticals, Deka Biosciences, HotSpot Therapeutics, Marengo Therapeutics<\/b> Stock, Other Business Ownership. <br><b>Lytix Biopharma, Eisai, Pierre Fabre, AstraZeneca, Servier, Roche, Redx Pharma, Sotio, Innate Pharma, ImCheck therapeutics, MSD, OSE Immunotherapeutics, HiFiBiO Therapeutics, Centessa Pharmaceuticals<\/b> Consulting or Advisory Role. <br><b>Clover Biopharmaceuticals, Shattuck Labs, Deka Biosciences, Hotspot Therapeutics, Medicxi, Depth Charge Therapeutics, BioLineRx, Gritstone Bio, Johnson & Johnson\/Janssen, Third Rock Ventures, Sanofi<\/b> Consulting or Advisory Role. <br><b>PegaOne, Guidepoint Global, Neogene Therapeutics, Gray Wolf Therapeutics, Adagene<\/b> Consulting or Advisory Role. <br><b>Monoclonal antibodies against CD81 (Stanford University)<\/b> Patent. <br><b>Bristol Myers Squibb, Roche\/Genentech, Incyte, MSD<\/b> Travel.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11471","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT181","PresenterBiography":null,"PresenterDisplayName":"Mounia Foucart","PresenterKey":"dc42a9d5-be05-46a5-bfd2-f69856144be0","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT181. First-in-human phase I of anti-VISTA monoclonal antibody W0180 with and without anti-PD-1 pembrolizumab in patients with locally advanced or metastatic solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"First-in-human phase I of anti-VISTA monoclonal antibody W0180 with and without anti-PD-1 pembrolizumab in patients with locally advanced or metastatic solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Oncolytic virus,Immuno-oncology,Immune checkpoint blockade,Immune cells,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>D. Li<\/b><sup>1<\/sup>, A. F. Shields<sup>2<\/sup>, H. Mamdani<sup>2<\/sup>, P. Travis<sup>3<\/sup>, G. Wright<sup>4<\/sup>, W. Akerley<sup>5<\/sup>, A. Spira<sup>6<\/sup>, G. Daniels<sup>7<\/sup>, J. Merchan<sup>8<\/sup>, A. Kumar<sup>9<\/sup>, E. Lim<sup>10<\/sup>, C. Egelston<sup>1<\/sup>, O. Flores<sup>1<\/sup>, S. Hamilton<sup>1<\/sup>, J. Austria<sup>1<\/sup>, A. Seiz<sup>11<\/sup>, S. Yavrom<sup>11<\/sup>, S. Fein<sup>11<\/sup>, J. Byon<sup>11<\/sup>, P. Woodard<sup>11<\/sup>, G. A. Wilkinson<sup>11<\/sup>, J. Leddon<sup>12<\/sup>; <br\/><sup>1<\/sup>City of Hope Comprehensive Cancer Center, Duarte, CA, <sup>2<\/sup>Barbara Ann Karmanos Cancer Institute, Detroit, MI, <sup>3<\/sup>Highlands Oncology, Fayetteville, AR, <sup>4<\/sup>St Vincent's Hospital Melbourne, Melbourne, Australia, <sup>5<\/sup>Huntsman Cancer Institute, Salt Lake City, UT, <sup>6<\/sup>New Experimental Therapeutics of Virginia - NEXT Oncology, Fairfax, VA, VA, <sup>7<\/sup>University of California San Diego, San Diego, CA, <sup>8<\/sup>University of Miami, Miami, FL, <sup>9<\/sup>University of Arizona, Tucson, AZ, <sup>10<\/sup>Spectrum Health Medical Group, Grand Rapids, MI, <sup>11<\/sup>Imugene Ltd., Sydney, Australia, <sup>12<\/sup>University of Cincinnati Cancer Center, Cincinnati, OH","CSlideId":"","ControlKey":"3b4bc9c3-664b-4681-9835-d43ddeafe880","ControlNumber":"9895","DisclosureBlock":"&nbsp;<b>D. Li, <\/b> None..<br><b>A. F. Shields, <\/b> None..<br><b>H. Mamdani, <\/b> None..<br><b>P. Travis, <\/b> None..<br><b>G. Wright, <\/b> None..<br><b>W. Akerley, <\/b> None..<br><b>A. Spira, <\/b> None..<br><b>G. Daniels, <\/b> None..<br><b>J. Merchan, <\/b> None..<br><b>A. Kumar, <\/b> None..<br><b>E. Lim, <\/b> None..<br><b>C. Egelston, <\/b> None..<br><b>O. Flores, <\/b> None..<br><b>S. Hamilton, <\/b> None..<br><b>J. Austria, <\/b> None.&nbsp;<br><b>A. Seiz, <\/b> <br><b>Imugene<\/b> Employment. <br><b>S. Yavrom, <\/b> <br><b>Imugene<\/b> Employment. <br><b>S. Fein, <\/b> <br><b>Imugene<\/b> Independent Contractor. <br><b>J. Byon, <\/b> <br><b>Imugene<\/b> Employment. <br><b>P. Woodard, <\/b> <br><b>Imugene<\/b> Employment. <br><b>G. A. Wilkinson, <\/b> <br><b>Imugene<\/b> Employment.<br><b>J. Leddon, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11472","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"8","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT182","PresenterBiography":null,"PresenterDisplayName":"Daneng Li, MD","PresenterKey":"19214f6f-2133-498c-8d6b-0175c5de1bc4","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT182. Oncolytic virus CF33-hNIS for the treatment of advanced cancer","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Oncolytic virus CF33-hNIS for the treatment of advanced cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Cytokines,Interleukin-2,Immunotherapy,Immuno-oncology,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"B. Izar<sup>1<\/sup>, D. Zamarin<sup>2<\/sup>, D. R. Spigel<sup>3<\/sup>, C. J. Hoimes<sup>4<\/sup>, D. F. McDermott<sup>5<\/sup>, K. Sehgal<sup>6<\/sup>, Y. G. Najjar<sup>7<\/sup>, A. J. Schoenfeld<sup>8<\/sup>, E. B. Garon<sup>9<\/sup>, R. J. Sullivan<sup>10<\/sup>, B. S. Henick<sup>1<\/sup>, T. A. Leal<sup>11<\/sup>, M. E. Hurwitz<sup>12<\/sup>, R. R. McKay<sup>13<\/sup>, N. Busby<sup>14<\/sup>, A. Mehta-Damani<sup>14<\/sup>, <b>A. Azrilevich<\/b><sup>14<\/sup>, T. Tran<sup>14<\/sup>, N. Rizvi<sup>14<\/sup>, M. Oft<sup>14<\/sup>, A. I. Spira<sup>15<\/sup>; <br\/><sup>1<\/sup>Columbia University Medical Center, New York, NY, <sup>2<\/sup>Icahn School of Medicine at Mount Sinai, New York, NY, <sup>3<\/sup>Sarah Cannon Research Institute, Nashville, TN, <sup>4<\/sup>Duke, Durham, NC, <sup>5<\/sup>Beth Israel Deaconess Medical Center, Boston, MA, <sup>6<\/sup>Dana Farber Cancer Institute, Boston, MA, <sup>7<\/sup>UPMC Hillman Cancer Center, Pittsburgh, PA, <sup>8<\/sup>Memorial Sloan Kettering Cancer Center, New York, NY, <sup>9<\/sup>University of California, Los Angeles, Los Angeles, CA, <sup>10<\/sup>Massachusetts General Hospital, Boston, MA, <sup>11<\/sup>Emory, Atlanta, GA, <sup>12<\/sup>Yale Cancer Center, New Haven, CT, <sup>13<\/sup>University of California San Diego, San Diego, CA, <sup>14<\/sup>Synthekine, Menlo Park, CA, <sup>15<\/sup>NEXT Oncology Virginia, Fairfax, VA","CSlideId":"","ControlKey":"153924fc-75bc-4102-8247-cef3dd524320","ControlNumber":"9771","DisclosureBlock":"<b>&nbsp;B. Izar, <\/b> <br><b>Volastra<\/b> Independent Contractor. <br><b>AstraZeneca<\/b> Independent Contractor. <br><b>Johnson & Johnson<\/b> Independent Contractor. <br><b>D. Zamarin, <\/b> <br><b>Astra Zeneca<\/b> Employment, Grant\/Contract. <br><b>Plexxikon<\/b> Grant\/Contract. <br><b>Merck<\/b> Other Intellectual Property. <br><b>Memgen<\/b> Independent Contractor. <br><b>GSK<\/b> Independent Contractor. <br><b>Hookipa<\/b> Independent Contractor. <br><b>Takeda<\/b> Independent Contractor. <br><b>Xencor<\/b> Independent Contractor. <br><b>Accuris Therapeutics<\/b> Stock Option. <br><b>Calidi Biotherapeutics<\/b> Stock Option. <br><b>immunos<\/b> Stock Option. <br><b>Synthekine<\/b> Independent Contractor. <br><b>D. R. Spigel, <\/b> <br><b>Agios<\/b> Other, Research Funding. <br><b>AbbVie<\/b> Independent Contractor, Other, Research Funding. <br><b>AstraZeneca<\/b> Independent Contractor, Other, Research Funding. <br><b>Bristol-Myers Squibb<\/b> Independent Contractor, Other, Research Funding. <br><b>GlaxoSmithKline<\/b> Independent Contractor, Other, Research Funding. <br><b>Ipsen Biopharmaceuticals<\/b> Independent Contractor, Other, Research Funding. <br><b>Jazz Pharmaceuticals<\/b> Independent Contractor, Other, Research Funding. <br><b>Lyell<\/b> Independent Contractor, Other, Research Funding. <br><b>MedImmune<\/b> Independent Contractor, Other, Research Funding. <br><b>Monte Rosa Therapeutics<\/b> Independent Contractor, Other, Research Funding. <br><b>Novartis<\/b> Independent Contractor, Other, Research Funding. <br><b>Novocure<\/b> Independent Contractor, Other, Research Funding. <br><b>Roche<\/b> Independent Contractor. <br><b>Zai Laboratory<\/b> Other, Research Funding. <br><b>Verastem<\/b> Other, Research Funding. <br><b>UT Southwestern<\/b> Other, Research Funding. <br><b>Transgene<\/b> Other, Research Funding. <br><b>Tizona Therapeutics<\/b> Other, Research Funding. <br><b>Rgenix<\/b> Other, Research Funding. <br><b>Seagen<\/b> Other, Research Funding. <br><b>C. J. Hoimes, <\/b> <br><b>Merck<\/b> Independent Contractor. <br><b>Seagen<\/b> Independent Contractor. <br><b>Eisai<\/b> Independent Contractor. <br><b>D. F. McDermott, <\/b> <br><b>Bristol-Myers Squibb<\/b> Independent Contractor, Grant\/Contract. <br><b>Pfizer<\/b> Independent Contractor, Grant\/Contract. <br><b>Merck<\/b> Independent Contractor, Grant\/Contract. <br><b>Alkermes, Inc.<\/b> Independent Contractor, Grant\/Contract. <br><b>EMD Serono<\/b> Independent Contractor. <br><b>Eli Lilly and Company<\/b> Independent Contractor. <br><b>Iovance<\/b> Independent Contractor. <br><b>Eisai Inc.<\/b> Independent Contractor. <br><b>Werewolf Therapeutics<\/b> Independent Contractor. <br><b>Calithera Biosciences<\/b> Independent Contractor. <br><b>Synthekine<\/b> Independent Contractor. <br><b>J&J<\/b> Independent Contractor. <br><b>Aveo<\/b> Independent Contractor. <br><b>Exelixis<\/b> Grant\/Contract. <br><b>X4 Pharma<\/b> Grant\/Contract. <br><b>Checkmate Pharmaceuticals<\/b> Grant\/Contract. <br><b>CRISPR Therapeutics<\/b> Grant\/Contract. <br><b>Genentech<\/b> Grant\/Contract. <br><b>K. Sehgal, <\/b> <br><b>Exelixis<\/b> Independent Contractor. <br><b>Merck<\/b> Independent Contractor. <br><b>Scholar Rock<\/b> Independent Contractor. <br><b>Equinox<\/b> Independent Contractor. <br><b>AmeriBergan<\/b> Independent Contractor. <br><b>Pri-Med<\/b> Independent Contractor. <br><b>Y. G. Najjar, <\/b> <br><b>BMS<\/b> Independent Contractor. <br><b>InterVenn Bio<\/b> Independent Contractor. <br><b>Immunocore<\/b> Independent Contractor. <br><b>Mallinkrodt<\/b> Independent Contractor. <br><b>Novartis<\/b> Independent Contractor. <br><b>Merck<\/b> Independent Contractor. <br><b>Pfizer<\/b> Independent Contractor. <br><b>Istari<\/b> Travel. <br><b>A. J. Schoenfeld, <\/b> <br><b>J&J<\/b> Independent Contractor. <br><b>KSQ therapeutics<\/b> Independent Contractor. <br><b>BMS<\/b> Independent Contractor, Other, Research Funding. <br><b>Merck<\/b> Independent Contractor, Other, Research Funding. <br><b>Enara Bio<\/b> Independent Contractor. <br><b>Perceptive Advisors<\/b> Independent Contractor. <br><b>Oppenheimer and Co<\/b> Independent Contractor. <br><b>Umoja Biopharma<\/b> Independent Contractor. <br><b>Legend Biotech<\/b> Independent Contractor. <br><b>Iovance Biotherapeutics<\/b> Independent Contractor, Other, Research Funding. <br><b>Prelude Therapeutics<\/b> Independent Contractor. <br><b>Immunocore<\/b> Independent Contractor. <br><b>Lyell Immunopharma<\/b> Independent Contractor. <br><b>Amgen<\/b> Independent Contractor, Other, Research Funding. <br><b>Heat Biologics<\/b> Independent Contractor. <br><b>GSK<\/b> Other, Research Funding. <br><b>PACT<\/b> Other, Research Funding. <br><b>Harpoon Therapeutics<\/b> Other, Research Funding. <br><b>Achilles Therapeutics<\/b> Other, Research Funding. <br><b>GSK<\/b> Other, Research Funding. <br><b>E. B. Garon, <\/b> <br><b>Abbvie<\/b> Independent Contractor. <br><b>Arcus<\/b> Independent Contractor. <br><b>Bristol-Myers Squibb<\/b> Independent Contractor, Grant\/Contract. <br><b>AstraZeneca<\/b> Independent Contractor, Grant\/Contract. <br><b>Atreca<\/b> Independent Contractor. <br><b>BridgeBio<\/b> Independent Contractor. <br><b>EMD Serono<\/b> Independent Contractor, Grant\/Contract. <br><b>Gilead<\/b> Independent Contractor, Grant\/Contract. <br><b>Eli Lilly<\/b> Independent Contractor, Grant\/Contract. <br><b>GlaxoSmithKline<\/b> Independent Contractor. <br><b>Hookipa<\/b> Independent Contractor. <br><b>Merck<\/b> Independent Contractor, Grant\/Contract. <br><b>Merus<\/b> Independent Contractor. <br><b>EMD Serono<\/b> Independent Contractor, Grant\/Contract. <br><b>LianBio<\/b> Independent Contractor. <br><b>Novartis<\/b> Independent Contractor, Grant\/Contract. <br><b>Sanofi<\/b> Independent Contractor. <br><b>Regeneron<\/b> Independent Contractor, Grant\/Contract. <br><b>Personalis<\/b> Independent Contractor. <br><b>Synthekine<\/b> Independent Contractor, Grant\/Contract. <br><b>R. J. Sullivan, <\/b> <br><b>Bristol Myers Squibb<\/b> Independent Contractor. <br><b>Eisai<\/b> Independent Contractor. <br><b>Iovance<\/b> Independent Contractor. <br><b>Merck<\/b> Independent Contractor. <br><b>Novartis<\/b> Independent Contractor, Grant\/Contract. <br><b>OncoSec<\/b> Independent Contractor. <br><b>Pfizer<\/b> Independent Contractor. <br><b>B. S. Henick, <\/b> <br><b>AstraZeneca<\/b> Other, Consultant. <br><b>Ideaya<\/b> Other, Consultant. <br><b>Jazz Pharmaceuticals<\/b> Other, Consultant. <br><b>Sorrento Therapeutics<\/b> Other, Consultant. <br><b>Genentech-Roche<\/b> Grant\/Contract. <br><b>Bristol-Myers Squib<\/b> Other, Consultant. <br><b>Janssen<\/b> Grant\/Contract. <br><b>Regeneron<\/b> Other, Consultant. <br><b>NextImmune<\/b> Grant\/Contract. <br><b>T. A. Leal, <\/b> <br><b>Novocure<\/b> Independent Contractor. <br><b>Amgen<\/b> Independent Contractor. <br><b>Roche\/Genentech<\/b> Independent Contractor. <br><b>Astrazeneca<\/b> Independent Contractor. <br><b>Regeneron<\/b> Independent Contractor. <br><b>Takeda<\/b> Independent Contractor. <br><b>Eisai<\/b> Independent Contractor. <br><b>Merck<\/b> Independent Contractor. <br><b>Jazz Pharmaceuticals<\/b> Independent Contractor. <br><b>Catalyst<\/b> Independent Contractor. <br><b>OncoC4<\/b> Independent Contractor. <br><b>Pfizer<\/b> Independent Contractor. <br><b>Janssen<\/b> Independent Contractor. <br><b>Novartis<\/b> Independent Contractor. <br><b>Sanofi<\/b> Independent Contractor. <br><b>BMS<\/b> Independent Contractor. <br><b>Abbvie<\/b> Independent Contractor. <br><b>Gilead<\/b> Independent Contractor. <br><b>M. E. Hurwitz, <\/b> <br><b>Affini-T<\/b> Independent Contractor. <br><b>Exelixis<\/b> Independent Contractor. <br><b>CRISPR Therapeutics<\/b> Independent Contractor, Other, Research. <br><b>Janssen<\/b> Independent Contractor. <br><b>Pliant<\/b> Independent Contractor. <br><b>Regeneron<\/b> Independent Contractor. <br><b>Tscan<\/b> Independent Contractor, Other, Research. <br><b>Bristol Myer Squibb<\/b> Other, Research. <br><b>AstraZeneca<\/b> Other, Research. <br><b>Astellas<\/b> Other, Research. <br><b>Arrowhead<\/b> Other, Research. <br><b>Apexigen<\/b> Other, Research. <br><b>Achilles Therapeutics<\/b> Other, Research. <br><b>Alpine<\/b> Other, Research. <br><b>Allogene<\/b> Other, Research. <br><b>Eli Lilly<\/b> Other, Research. <br><b>Endocyte<\/b> Other, Research. <br><b>Merck<\/b> Other, Research. <br><b>Novartis<\/b> Other, Research. <br><b>Pfizer<\/b> Other, Research. <br><b>R. R. McKay, <\/b> <br><b>AstraZeneca<\/b> Independent Contractor, Grant\/Contract. <br><b>Aveo<\/b> Independent Contractor. <br><b>Blue Earth Diagnostics<\/b> Independent Contractor. <br><b>Bristol-Myers Squibb<\/b> Independent Contractor, Grant\/Contract. <br><b>Calithera<\/b> Independent Contractor. <br><b>Caris<\/b> Independent Contractor. <br><b>Dendreon<\/b> Independent Contractor. <br><b>Johnson & Johnson<\/b> Independent Contractor. <br><b>Eisai<\/b> Independent Contractor. <br><b>Exelixis<\/b> Independent Contractor, Grant\/Contract. <br><b>Myovant<\/b> Independent Contractor. <br><b>Lilly<\/b> Independent Contractor. <br><b>Merck<\/b> Independent Contractor. <br><b>Novartis<\/b> Independent Contractor. <br><b>Pfizer<\/b> Independent Contractor. <br><b>Sanofi<\/b> Independent Contractor. <br><b>SeaGen<\/b> Independent Contractor. <br><b>Sorrento Therapeutics<\/b> Independent Contractor. <br><b>Telix<\/b> Independent Contractor. <br><b>Tempus<\/b> Independent Contractor. <br><b>N. Busby, <\/b> <br><b>Synthekine<\/b> Employment. <br><b>A. Mehta-Damani, <\/b> <br><b>Synthekine<\/b> Employment. <br><b>A. Azrilevich, <\/b> <br><b>Synthekine<\/b> Employment. <br><b>T. Tran, <\/b> <br><b>Synthekine<\/b> Employment. <br><b>N. Rizvi, <\/b> <br><b>Synthekine<\/b> Employment. <br><b>M. Oft, <\/b> <br><b>Synthekine<\/b> Employment. <br><b>A. I. Spira, <\/b> <br><b>Eli Lilly<\/b> Independent Contractor, Stock. <br><b>CytomX Therapeutics<\/b> Independent Contractor. <br><b>AstraZeneca\/MedImmune<\/b> Independent Contractor. <br><b>Merck<\/b> Independent Contractor. <br><b>Takeda<\/b> Independent Contractor. <br><b>Amgen<\/b> Independent Contractor. <br><b>Janssen Oncology<\/b> Independent Contractor. <br><b>Novartis<\/b> Independent Contractor. <br><b>Bristol-Myers Squibb<\/b> Independent Contractor. <br><b>Bayer<\/b> Independent Contractor. <br><b>Incyte<\/b> Independent Contractor. <br><b>Mirati Therapeutics<\/b> Independent Contractor. <br><b>Gritstone<\/b> Independent Contractor. <br><b>Jazz Pharmaceuticals<\/b> Independent Contractor. <br><b>Mersana<\/b> Independent Contractor. <br><b>Daiichi Sankyo\/Astra Zeneca<\/b> Independent Contractor. <br><b>Regeneron<\/b> Independent Contractor. <br><b>Sanofi<\/b> Independent Contractor. <br><b>Array<\/b> Independent Contractor. <br><b>Blueprint<\/b> Independent Contractor.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11473","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT183","PresenterBiography":null,"PresenterDisplayName":"Alex Azrilevich, Pharm D","PresenterKey":"527cc8a3-7938-4f75-a3b3-d560499bc7aa","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT183. Initial results from a phase 1a\/1b study of STK-012, a first-in-class &#945;\/&#946; IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Initial results from a phase 1a\/1b study of STK-012, a first-in-class &#945;\/&#946; IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Phase I,Immune checkpoint blockade,TIGIT,Antibody,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. Naing<\/b><sup>1<\/sup>, M. McKean<sup>2<\/sup>, A. Tolcher<sup>3<\/sup>, A. Victor<sup>4<\/sup>, P. Hu<sup>5<\/sup>, K. T. Mehr<sup>4<\/sup>, T. Kitzing<sup>4<\/sup>, D. Holland<sup>4<\/sup>, E. Richter<sup>4<\/sup>, L. Siu<sup>6<\/sup>; <br\/><sup>1<\/sup>UT MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN, <sup>3<\/sup>NEXT Oncology and Texas Oncology, San Antonio, TX, <sup>4<\/sup>the healthcare business of Merck KGaA, Darmstadt, Germany, <sup>5<\/sup>EMD Serono, Billerica, MA, <sup>6<\/sup>Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada","CSlideId":"","ControlKey":"d281888f-a4fe-428f-9d87-9f4af553e370","ControlNumber":"10342","DisclosureBlock":"<b>&nbsp;A. Naing, <\/b> <br><b>Novartis, CytomX Therapeutics, OncoSec, STCube Pharmaceuticals Inc, Kymab, Takeda (I), CSL Behring (I), Horizon Pharma (I), Genome & Company, Immune-Onc, Deka Bioscience, and Nouscom<\/b> Other, Consultant. <br><b>EMD Serono, Billerica, MA, USA; MedImmune; Atterocor; Amplimmune; ARMO BioSciences; Karyopharm Therapeutics; Incyte; Novartis; Regeneron<\/b> Grant\/Contract. <br><b>the healthcare business of Merck KGaA, Darmstadt, Germany; Bristol Myers Squibb; Pfizer; CytomX Therapeutics; Neon Therapeutics; Calithera Biosciences; TopAlliance BioSciences Inc.; Healios; Lilly<\/b> Grant\/Contract. <br><b>Kymab, PsiOxus Therapeutics, Immune Deficiency Foundation (I), Arcus Biosciences, NeoImmuneTech, ImmuneOncia, Surface Oncology, and Baxalta (I)<\/b> Grant\/Contract. <br><b>ARMO BioSciences<\/b> Travel. <br><b>M. McKean, <\/b> <br><b>Astellas Pharma, AstraZeneca, BicycleTX Limited, Castle Biosciences, Eisai, Ideaya Biosciences, iTeos, Moderna, Pfizer, and Regeneron Pharmaceuticals<\/b> Other, Consultant. <br><b>Alpine Immune Sciences, Arcus Biosciences, Arvinas, Ascentage Pharma Group, Bayer, Bicycle Therapeutics, BioMed Valley Discoveries, BioNTech, Dragonfly Therapeutics; EMD Serono, Billerica, MA, USA;<\/b> Grant\/Contract. <br><b>Epizyme, Erasca, Exelixis, Foghorn Therapeutics, Genentech, Gilead Sciences, GSK, IDEAYA Biosciences, Ikena Oncology, ImmVira Pharma, Infinity Pharmaceuticals, Jacobio Pharmaceuticals, Kechow Pharma<\/b> Grant\/Contract. <br><b>Kezar Life Sciences, Kinnate BioPharma, MedImmune, Mereo BioPharma, Metabomed, Moderna, NBE Therapeutics, Nektar, Novartis, Oncorus, PACT Pharma, Pfizer<\/b> Grant\/Contract. <br><b>Plexxikon, Prelude Therapeutics, Pyramid Biosciences, Regeneron, Sapience Therapeutics, Scholar Rock, Seattle Genetics, Synthrox, Takeda Pharmaceuticals, Teneobio, Tempest Therapeutics<\/b> Grant\/Contract. <br><b>Tizona Therapeutics, TMUNITY Therapeutics, TopAlliance Biosciences, Xilio<\/b> Grant\/Contract. <br><b>A. Tolcher, <\/b> <br><b>Nanobiotix, Pierre Fabre, Ascentage Pharma, AbbVie; EMD Serono, Billerica, MA, USA; Bioinvent, Adagene, Agenus, Aximmune, Bayer, HBM Partners, Mekanistic, NBE Therapeutics, Pelican, Pfizer, Immunome<\/b> Other, Consultant. <br><b>Gilde Healthcare Partners, Immunomet, Mirati Therapeutics, Pieris, Aro Biotherapeutics, Asana, Elucida, Partner Therapeutics, Ryvu Therapeutics, Sotio, Eleven Bio, Zymeworks, Mersana<\/b> Other, Consultant. <br><b>Trillium Therapeutics, Boehringer Ingelheim International GmbH; Janssen Global Services, LLC; Aclaris Therapeutics, Blu Print Oncology; Daiichi Sankyo, Inc.; IDEA Pharma, Immuneering<\/b> Other, Consultant. <br><b>Impact Therapeutics US, Inc., Karma Oncology, Lengo Therapeutics, Menarini Ricerche, Seattle Genetics, SK Life Sciences, Spirea Limited Inc, Sunshine Guojian, Transcenta Therapeutics, Zentalis<\/b> Other, Consultant. <br><b>Transgene, Deka Biosciences, Hiber Cell, Inc., Ikena Oncology, Jazz Pharmaceuticals, PYXIS Oncology, Vincerx Pharma, ZielBio, Senti Biosciences, Ocellaris Pharma, Lilly<\/b> Other, Consultant. <br><b>AbbVie, Pfizer, Syndax, Asana Biosciences, ADC Therapeutics, Adagene, Aminex, Ascentage Pharma, Arrys, CStone Pharmaceuticals, Deciphera, GSK, Inhibrx, Innate Pharma, Kiromic, Mersana, Naturewise<\/b> Grant\/Contract. <br><b>NextCure, Nitto BioPharma, Pieris Pharmaceuticals, Symphogen, Tizona Therapeutics, Inc., Zymeworks, Agenus, Amphivena, Astex, Boehringer Ingelheim, Basilea, eFFECTOR Therapeutics<\/b> Grant\/Contract. <br><b>EMD Serono, Billerica, MA, USA; Gilead Sciences, KeChow, K Group Beta, Janssen Research & Development, Merck & Co., ORIC Pharmaceuticals, Samumed, Spring Bank, Seattle Genetics<\/b> Grant\/Contract. <br><b>Sunshine Guojian, Synthorx, Bioinvent International AB, Birdie Biopharmaceuticals, BJ Bioscience Inc., Boston Biomedical, Inc., Daiichi Sankyo, Inc., ImmuneOncia Therapeutics Inc.<\/b> Grant\/Contract. <br><b>NBE Therapeutics AG, Odonate Therapeutics Inc., Qilu Puget Sound Biotherapeutics Corp, Shanghai Haihe Pharmaceutical Co., Ltd., Takeda, ABL Bio, Apros Therapeutics, Arcellx, ARMO BioSciences<\/b> Grant\/Contract. <br><b>Artios Pharma Limited, Mirati Therapeutics Inc.<\/b> Grant\/Contract. <br><b>Immunogen<\/b> Other, testimony compensation. <br><b>Sotio<\/b> Travel. <br><b>A. Victor, <\/b> <br><b>the healthcare business of Merck KGaA, Darmstadt, Germany<\/b> Employment. <br><b>Merck KGaA, Darmstadt, Germany<\/b> Stock, Other, shares. <br><b>P. Hu, <\/b> <br><b>EMD Serono, Billerica, MA, USA<\/b> Employment. <br><b>Merck KGaA, Darmstadt, Germany<\/b> Stock, Other, shares. <br><b>K. T. Mehr, <\/b> <br><b>the healthcare business of Merck KGaA, Darmstadt, Germany<\/b> Employment. <br><b>Merck KGaA, Darmstadt, Germany<\/b> Stock, Other, shares. <br><b>T. Kitzing, <\/b> <br><b>the healthcare business of Merck KGaA, Darmstadt, Germany<\/b> Employment. <br><b>Merck KGaA, Darmstadt, Germany<\/b> Stock, Other, shares. <br><b>D. Holland, <\/b> <br><b>the healthcare business of Merck KGaA, Darmstadt, Germany<\/b> Employment. <br><b>Merck KGaA, Darmstadt, Germany<\/b> Stock, Other, shares. <br><b>E. Richter, <\/b> <br><b>the healthcare business of Merck KGaA, Darmstadt, Germany<\/b> Employment. <br><b>Merck KGaA, Darmstadt, Germany<\/b> Stock, Other, shares. <br><b>L. Siu, <\/b> <br><b>Merck & Co., AstraZeneca\/MedImmune, Roche, Voronoi Inc., Oncorus, GSK, Seattle Genetics, Arvinas, Navire, Janpix, Relay Therapeutics, Daiichi Sankyo\/UCB Japan, Janssen, Hookipa Pharma, InterRNA<\/b> Other, Consultant. <br><b>Tessa Therapeutics, Sanofi, and Amgen<\/b> Other, Consultant. <br><b>BMS, Genentech\/Roche, GSK, Merck & Co., Novartis, Pfizer, AstraZeneca, Boehringer Ingelheim, Bayer, Amgen, Astellas Pharma, Shattuck Labs, Symphogen, Avid, Mirati Therapeutics, Intensity Therapeutics<\/b> Grant\/Contract. <br><b>Karyopharm Therapeutics<\/b> Grant\/Contract.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11474","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"10","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT184","PresenterBiography":"","PresenterDisplayName":"Aung Naing, MD","PresenterKey":"40ef8f10-c4dd-4e2c-b6b5-ddb895b62d12","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT184. First-in-human trial of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with advanced solid unresectable tumors","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"First-in-human trial of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with advanced solid unresectable tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Immune checkpoint blockade,TIM-3,FIH,Solid tumors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Y.-L. Wu<\/b><sup>1<\/sup>, H. Chen<sup>1<\/sup>, S. Wang<sup>2<\/sup>, R. Zhang<sup>2<\/sup>, E.-T. Tang<sup>2<\/sup>, W. Zhang<sup>2<\/sup>, K. Gu<sup>2<\/sup>, Y. Wang<sup>2<\/sup>, Y. Hei<sup>2<\/sup>; <br\/><sup>1<\/sup>Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, GuangZhou, China, GuangZhou, China, <sup>2<\/sup>Biocity Biopharmaceutics Co,.Ltd, Wuxi, China, shanghai, China","CSlideId":"","ControlKey":"6919d3a5-08ca-4e9e-8b65-761a2718346f","ControlNumber":"9512","DisclosureBlock":"&nbsp;<b>Y. Wu, <\/b> None..<br><b>H. Chen, <\/b> None.&nbsp;<br><b>S. Wang, <\/b> <br><b>Biocity Biopharmaceutics Co,.Ltd, Wuxi, China<\/b> Employment. <br><b>R. Zhang, <\/b> <br><b>Biocity Biopharmaceutics Co,.Ltd, Wuxi, China<\/b> Employment. <br><b>E. Tang, <\/b> <br><b>Biocity Biopharmaceutics Co,.Ltd, Wuxi, China<\/b> Employment. <br><b>W. Zhang, <\/b> <br><b>Biocity Biopharmaceutics Co,.Ltd, Wuxi, China<\/b> Employment. <br><b>K. Gu, <\/b> <br><b>Biocity Biopharmaceutics Co,.Ltd, Wuxi, China<\/b> Employment. <br><b>Y. Wang, <\/b> <br><b>Biocity Biopharmaceutics Co,.Ltd, Wuxi, China<\/b> Employment. <br><b>Y. Hei, <\/b> <br><b>Biocity Biopharmaceutics Co,.Ltd, Wuxi, China<\/b> Employment.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11475","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"13","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT185","PresenterBiography":null,"PresenterDisplayName":"Yi-Long Wu, Unknown","PresenterKey":"458f18f9-7cd8-4e31-b859-8f0fb9d2402f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT185. A phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BC3402 in advanced solid malignancies<b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BC3402 in advanced solid malignancies<b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Oncolytic virus,Immunotherapy,Pembrolizumab,Combination therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"M. Voskoboynik<sup>1<\/sup>, J. Liu<sup>2<\/sup>, K.-H. Song<sup>3<\/sup>, D.-G. Park<sup>3<\/sup>, M.-H. Ryu<sup>4<\/sup>, H. Chon<sup>5<\/sup>, <b>C. Kim<\/b><sup>5<\/sup>; <br\/><sup>1<\/sup>Department of Medical Oncology, The Alfred, Australia Central Clinical School, Monash University, Melbourne, Australia, <sup>2<\/sup>Department of Medical Oncology, The Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, Australia, <sup>3<\/sup>ViroCure, Seoul, Korea, Republic of, <sup>4<\/sup>Department of Oncology, Asan Medical Center,  University of Ulsan College of Medicine, Seoul, Korea, Republic of, <sup>5<\/sup>Medical Oncology, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam, Korea, Republic of","CSlideId":"","ControlKey":"2ab132da-348e-46b0-a4a0-d53634178ae7","ControlNumber":"9678","DisclosureBlock":"&nbsp;<b>M. Voskoboynik, <\/b> None..<br><b>J. Liu, <\/b> None.&nbsp;<br><b>K. Song, <\/b> <br><b>Virocure<\/b> Employment. <br><b>D. Park, <\/b> <br><b>Virocure<\/b> Employment. <br><b>M. Ryu, <\/b> <br><b>Virocure<\/b> Grant\/Contract. <br><b>H. Chon, <\/b> <br><b>Virocure<\/b> Grant\/Contract. <br><b>C. Kim, <\/b> <br><b>Virocure<\/b> Grant\/Contract.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11476","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT186","PresenterBiography":"","PresenterDisplayName":"Chan Kim, MD;PhD","PresenterKey":"69e6c2ed-28ec-463a-9a2e-8c8c190cd744","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT186. A first-in-human phase 1 dose-escalation and expansion study of intratumoral oncolytic reovirus (RC402) as a monotherapy or in combination with pembrolizumab in advanced solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A first-in-human phase 1 dose-escalation and expansion study of intratumoral oncolytic reovirus (RC402) as a monotherapy or in combination with pembrolizumab in advanced solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Drug delivery,Tumor microenvironment,Cancer associated fibroblasts,Fibroblast Activation Protein (FAP),"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>U. Banerji<\/b><sup>1<\/sup>, N. Cook<sup>2<\/sup>, A. Anthoney<sup>3<\/sup>, R. Plummer<sup>4<\/sup>, W. D. Tap<sup>5<\/sup>, J. T. R. Evans<sup>6<\/sup>, L. D. Cranmer<sup>7<\/sup>, C. Plummer<sup>8<\/sup>, P. Loadman<sup>9<\/sup>, G. Lahu<sup>10<\/sup>, H. S. Jones<sup>9<\/sup>, N. Kinnersley<sup>11<\/sup>, F. McLaughlin<sup>12<\/sup>, C. Twelves<sup>8<\/sup>; <br\/><sup>1<\/sup>The Institute of Cancer Research, Sutton, Sutton, United Kingdom, <sup>2<\/sup>The Christie NHS Foundation Trust, Manchester, United Kingdom, <sup>3<\/sup>The University of Leeds, Leeds, United Kingdom, <sup>4<\/sup>Newcastle University, Newcastle, United Kingdom, <sup>5<\/sup>Memorial Sloan Kettering Cancer Center, New York, NY, <sup>6<\/sup>University of Glasgow, Glasgow, United Kingdom, <sup>7<\/sup>University of Washington Fred Hutchinson Cancer Center, Seattle, WA, <sup>8<\/sup>University of Leeds, Leeds, United Kingdom, <sup>9<\/sup>University of Bradford, Bradford, United Kingdom, <sup>10<\/sup>ThinkQ2 AG, Baar, Switzerland, <sup>11<\/sup>Octa Consulting Group, Harpenden, United Kingdom, <sup>12<\/sup>Avacta Therapeutics, London, United Kingdom","CSlideId":"","ControlKey":"f645d6ac-2bb0-41d9-84a5-15228169f6c9","ControlNumber":"10666","DisclosureBlock":"<b>&nbsp;U. Banerji, <\/b> <br><b>Phoenix Solutions; PharmEnable; Ellipses Pharma<\/b> Grant\/Contract, Advisory board. <br><b>AstraZeneca; Onyx; Chugai; BTG; Verastem<\/b> Grant\/Contract, Research funding. <br><b>N. Cook, <\/b> <br><b>Roche; RedEx<\/b> Grant\/Contract, Advisory boards. <br><b>AstraZeneca, Orion, F. Hoffmann-La Roche Ltd, Taiho, GSK, Novartis, Starpharma, Bayer, Eisai, UCB, RedX Pharmaceuticals, Stemline Therapeutics, LOXO-oncology, Avacta, Boehringer Ingelheim, Merck, Tar<\/b> Grant\/Contract, Research funding.<br><b>A. Anthoney, <\/b> None.&nbsp;<br><b>R. Plummer, <\/b> <br><b>Pierre Faber, Bayer, Novartis, BMS, Ellipses, Immunocore, Genmab, Astex Therapeutics, MSD, Nerviano, AmLo, Incyte, Cybrexa Benevolent AI and Sanofi Aventis<\/b> Grant\/Contract, Advisory board. <br><b>Alligator Biosciences, GSK, Onxeo, SOTIO Biotech AG, and AstraZeneca<\/b> Grant\/Contract, IDMC honoraria. <br><b>AstraZeneca, Novartis, Bayer, MSD and BMS<\/b> Grant\/Contract, Travel, Educational talks with grant\/travel. <br><b>W. D. Tap, <\/b> <br><b>Atropos; Certis<\/b> Stock. <br><b>AmMax; Amgen; BioAtla; Boehringer Ingelheim; Cogent; Daiichi Sankyo; Deciphera; InhibRx; Servier; Per Events; PVI<\/b> Grant\/Contract, Research Funding\/Advisory board. <br><b>J. T. R. Evans, <\/b> <br><b>Ascelia, Astra Zeneca, Bayer, Bicycle Therapeutics, Bristol-Myers Squibb, Celgene, Eisai, Karus Therapeutics, Medivir, MSD, Otsuka, Roche, and Seagen<\/b> Grant\/Contract, Honoraria. <br><b>Astra Zeneca, Ascelia, Bayer, Bristol Myers Squibb, Celgene, Eisai, Nucana, MSD, Roche, Medivir, and United Medical<\/b> Grant\/Contract, Speaker fees. <br><b>Bristol-Myers Squibb; Roche; MSD; Pierre-Fabre; Celgene; Bayer<\/b> Travel. <br><b>Astra Zeneca, Basilea, Bayer, Celgene, MiNa Therapeutics, Roche, Pfizer, Sierra, Lilly, Eisai, GSK, Novartis, Bicycle Therapeutics, Johnson and Johnson, CytomX, Vertex, Plexxikon, Boehringer, Athinex<\/b> Grant\/Contract, Clinical trial grants to institution. <br><b>L. D. Cranmer, <\/b> <br><b>Blueprint Medicines<\/b> Grant\/Contract, Advisory board. <br><b>AADi; Advenchem, Lilly<\/b> Grant\/Contract, Research funding. <br><b>C. Plummer, <\/b> <br><b>Amgen; Servier<\/b> Grant\/Contract, Honoraria. <br><b>P. Loadman, <\/b> <br><b>Avacta<\/b> Grant\/Contract, Paid consultant. <br><b>G. Lahu, <\/b> <br><b>ThinkQ2 AG<\/b> Employment. <br><b>Avacta<\/b> Grant\/Contract, Paid consultant. <br><b>H. S. Jones, <\/b> <br><b>Avacta<\/b> Grant\/Contract, Paid consultant. <br><b>N. Kinnersley, <\/b> <br><b>Avacta<\/b> Grant\/Contract, Paid consultant. <br><b>F. McLaughlin, <\/b> <br><b>Avacta<\/b> Employment. <br><b>C. Twelves, <\/b> <br><b>MSD, Eisai, Daiichi-Sankyo, AstraZeneca, Pfizer, Lilly, Novartis and Gilead<\/b> Grant\/Contract, Travel, Advisory boards and research funding.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11478","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT188","PresenterBiography":null,"PresenterDisplayName":"Udai Banerji, MD;PhD","PresenterKey":"65fbff29-a51b-4389-a28d-e9e5c403aaeb","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT188. A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Immunotherapy,PI3K,PD-1,Solid tumors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>R. Cosman<\/b><sup>1<\/sup>, E. Ahern<sup>2<\/sup>, J. Li<sup>3<\/sup>, H. K. Gan<sup>4<\/sup>, Y. Chen<sup>5<\/sup>, B. Gao<sup>6<\/sup>, Y. Wang<sup>7<\/sup>, X. Mu<sup>8<\/sup>, H. Cheng<sup>9<\/sup>, Y. Qian<sup>8<\/sup>, H. Zhang<sup>9<\/sup>, K. Cao<sup>10<\/sup>; <br\/><sup>1<\/sup>Saint Vincent's Hospital, Sydney, Australia, <sup>2<\/sup>Monash Health, Clayton, Victoria, Australia, <sup>3<\/sup>Jining No. 1 People's Hospital, Shandong, China, <sup>4<\/sup>Austin Health, Melbourne, Victoria, Australia, <sup>5<\/sup>Fujian Cancer Hospital, Fujian, China, <sup>6<\/sup>Blacktown Cancer and Haematology Centre, Blacktown, Australia, <sup>7<\/sup>West China Hospital, Sichuan University, Sichuan, China, <sup>8<\/sup>BeiGene (Shanghai) Co., Ltd., Shanghai, China, <sup>9<\/sup>BeiGene USA, Inc., San Mateo, CA, <sup>10<\/sup>The Third Xiangya Hospital of Central South University, Hunan, China","CSlideId":"","ControlKey":"e9136716-4564-4ba8-b25e-1bf462e5f5bc","ControlNumber":"9897","DisclosureBlock":"&nbsp;<b>R. Cosman, <\/b> None.&nbsp;<br><b>E. Ahern, <\/b> <br><b>Amgen<\/b> Other, MSD and research funding (institution).<br><b>J. Li, <\/b> None..<br><b>H. K. Gan, <\/b> None..<br><b>Y. Chen, <\/b> None..<br><b>B. Gao, <\/b> None..<br><b>Y. Wang, <\/b> None.&nbsp;<br><b>X. Mu, <\/b> <br><b>BeiGene<\/b> Employment. <br><b>H. Cheng, <\/b> <br><b>BeiGene<\/b> Employment, Stock, Stock Option. <br><b>Y. Qian, <\/b> <br><b>BeiGene<\/b> Employment. <br><b>H. Zhang, <\/b> <br><b>BeiGene<\/b> Employment, Stock, Stock Option.<br><b>K. Cao, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11479","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"14","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT189","PresenterBiography":"","PresenterDisplayName":"Kayla Hayes, BA","PresenterKey":"aa2be8be-745d-491a-8832-1ceb669bcfcd","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT189. A first&#8209;in&#8209;human, phase 1a, dose&#8209;escalation study of BGB&#8209;10188, a phosphatidylinositol 3&#8209;kinase delta (PI3K&#948;) inhibitor, + tislelizumab (anti-PD-1) in patients with solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A first&#8209;in&#8209;human, phase 1a, dose&#8209;escalation study of BGB&#8209;10188, a phosphatidylinositol 3&#8209;kinase delta (PI3K&#948;) inhibitor, + tislelizumab (anti-PD-1) in patients with solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"PD-L1,Immuno-oncology,Checkpoint Inhibitors,Tumor microenvironment,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>B. A. Van Tine<\/b><sup>1<\/sup>, E. Ahn<sup>2<\/sup>, R. A. Redman<sup>3<\/sup>, M. A. Barve<sup>4<\/sup>, W. J. Edenfield<sup>5<\/sup>, J. Peguero<sup>6<\/sup>, V. M. Villaflor<sup>7<\/sup>, D. W. Rasco<sup>8<\/sup>, S. F. Powell<sup>9<\/sup>, A. T. Mamuye<sup>10<\/sup>, C. B. Moore<sup>10<\/sup>, J. M. Pelham<sup>10<\/sup>, S. Charoenthongtrakul<sup>10<\/sup>, D. R. Spigel<sup>11<\/sup>; <br\/><sup>1<\/sup>Washington University in St. Louis School of Medicine, St. Louis, MO, <sup>2<\/sup>Cancer Treatment Centers of America - Chicago (City of Hope), Chicago, IL, <sup>3<\/sup>University of Louisville, Louisville, KY, <sup>4<\/sup>Mary Crowley Cancer Research Center, Dallas, TX, <sup>5<\/sup>Prisma Health, Greenville, SC, <sup>6<\/sup>Oncology Consultants, Houston, TX, <sup>7<\/sup>City of Hope, Duarte, CA, <sup>8<\/sup>START, San Antonio, TX, <sup>9<\/sup>Sanford Cancer Center, Sioux Falls, SD, <sup>10<\/sup>Molecular Templates, Inc., Austin, TX, <sup>11<\/sup>Sarah Cannon Research Institute\/Tennessee Oncology, Nashville, TN","CSlideId":"","ControlKey":"2e751370-e326-4f5b-afcb-999068c73fe3","ControlNumber":"10434","DisclosureBlock":"<b>&nbsp;B. A. Van Tine, <\/b> <br><b>Polaris<\/b> Other, Leadership. <br><b>Adaptimmune<\/b> Independent Contractor, Travel, Other, Speakers' Bureau. <br><b>ADRx<\/b> Independent Contractor. <br><b>Apexigen<\/b> Independent Contractor. <br><b>Bayer<\/b> Independent Contractor. <br><b>Cytokinetics<\/b> Independent Contractor. <br><b>Daiichi Sankyo<\/b> Independent Contractor. <br><b>Deciphera Pharmaceuticals<\/b> Independent Contractor. <br><b>EMD Serono<\/b> Independent Contractor. <br><b>Epizyme<\/b> Independent Contractor. <br><b>GlaxoSmithKline<\/b> Independent Contractor, Grant\/Contract, Travel, Other, Speaker's Bureau. <br><b>Immune Design<\/b> Independent Contractor. <br><b>Lilly<\/b> Independent Contractor, Travel, Other, Speaker's Bureau. <br><b>Novartis<\/b> Independent Contractor, Other, Speaker's Bureau. <br><b>Pfizer<\/b> Independent Contractor, Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract. <br><b>TRACON Pharma<\/b> Grant\/Contract. <br><b>Accuronix Therapeutics<\/b> Patent. <br><b>Health Advances<\/b> Other, Expert Testimony. <br><b>Advanchen Laboratories<\/b> Travel.<br><b>E. Ahn, <\/b> None.&nbsp;<br><b>R. A. Redman, <\/b> <br><b>ALX Oncology<\/b> Grant\/Contract. <br><b>Daiichi Sankyo<\/b> Grant\/Contract. <br><b>Inspirna<\/b> Grant\/Contract. <br><b>Iovance<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>RAPT Therapeutics<\/b> Grant\/Contract. <br><b>M. A. Barve, <\/b> <br><b>Texas Oncology<\/b> Employment, Stock. <br><b>Mary Crowley Research Center<\/b> Grant\/Contract. <br><b>W. J. Edenfield, <\/b> <br><b>Chimerix<\/b> Independent Contractor. <br><b>J. Peguero, <\/b> <br><b>Texas Oncology<\/b> Employment, Independent Contractor. <br><b>V. M. Villaflor, <\/b> <br><b>ARIAD\/Takeda<\/b> Independent Contractor, Travel. <br><b>AstraZeneca<\/b> Independent Contractor, Travel. <br><b>Genentech\/Roche<\/b> Independent Contractor. <br><b>Bristol Myers Squibb<\/b> Independent Contractor, Travel. <br><b>Novacure<\/b> Independent Contractor, Travel. <br><b>Gilead<\/b> Independent Contractor, Travel. <br><b>Regeneron<\/b> Independent Contractor, Travel. <br><b>Johnson & Johnson<\/b> Stock. <br><b>Takeda Science Foundation<\/b> Grant\/Contract. <br><b>D. W. Rasco, <\/b> <br><b>Abbvie<\/b> Grant\/Contract. <br><b>Apexian Pharmaceuticals<\/b> Grant\/Contract. <br><b>Asana Biosciences<\/b> Grant\/Contract, Travel. <br><b>Ascentage Pharma<\/b> Grant\/Contract. <br><b>Astex Pharmaceuticals<\/b> Grant\/Contract. <br><b>Celgene<\/b> Grant\/Contract. <br><b>Compugen<\/b> Grant\/Contract. <br><b>Constellation Pharmaceuticals<\/b> Grant\/Contract. <br><b>Coordination Therapeutics<\/b> Grant\/Contract. <br><b>Eisai<\/b> Grant\/Contract. <br><b>Five Prime Therapeutics<\/b> Grant\/Contract. <br><b>GlaxoSmithKline<\/b> Grant\/Contract. <br><b>Gossamer Bio<\/b> Grant\/Contract. <br><b>Incyte<\/b> Grant\/Contract. <br><b>Macrogenics<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract. <br><b>Seven and Eight Biopharmaceuticals<\/b> Grant\/Contract. <br><b>Syndax<\/b> Grant\/Contract. <br><b>S. F. Powell, <\/b> <br><b>Bristol Myers Squibb<\/b> Independent Contractor, Grant\/Contract. <br><b>Genentech\/Roche<\/b> Grant\/Contract. <br><b>Incyte<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract. <br><b>Sharpe & Dohme<\/b> Grant\/Contract. <br><b>Novartis<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Vyriad<\/b> Grant\/Contract. <br><b>Seattle Genetics<\/b> Grant\/Contract. <br><b>Actuate<\/b> Grant\/Contract. <br><b>Sorrento<\/b> Grant\/Contract. <br><b>Alkermes<\/b> Other, Speaker's Bureau. <br><b>A. T. Mamuye, <\/b> <br><b>Molecular Templates<\/b> Employment. <br><b>C. B. Moore, <\/b> <br><b>Molecular Templates<\/b> Employment. <br><b>J. M. Pelham, <\/b> <br><b>Molecular Templates<\/b> Employment. <br><b>S. Charoenthongtrakul, <\/b> <br><b>Molecular Templates<\/b> Employment. <br><b>D. R. Spigel, <\/b> <br><b>ASCO<\/b> Other, Leadership. <br><b>Amgen, Aptitude, Bayer, Celgene, Curio Science, Dracen, Iksuda Therapeutics, Illumina, Intellisphere, Evelo Therapeutics, Exelixis, Illumina, Intellisphere, Jazz Pharmaceuticals, Mirati Therapeutics<\/b> Independent Contractor. <br><b>AstraZeneca<\/b> Independent Contractor, Grant\/Contract, Travel. <br><b>Bristol Myers Squibb<\/b> Independent Contractor, Grant\/Contract. <br><b>EMD Serono<\/b> Independent Contractor, Grant\/Contract. <br><b>Genentech\/Roche<\/b> Independent Contractor, Grant\/Contract. <br><b>GlaxoSmithKline<\/b> Independent Contractor, Grant\/Contract. <br><b>PharmaMar, Puma Biotechnology, Regeneron, Sanofi\/Aventis, Seattle Genetics, TRIPTYCH Health Partners, TRM Oncology<\/b> Independent Contractor. <br><b>Merck<\/b> Independent Contractor, Grant\/Contract. <br><b>Nektar<\/b> Independent Contractor, Grant\/Contract. <br><b>Novartis<\/b> Independent Contractor, Grant\/Contract, Travel. <br><b>Novocure<\/b> Independent Contractor, Grant\/Contract. <br><b>Pfizer<\/b> Independent Contractor, Grant\/Contract. <br><b>Takeda<\/b> Independent Contractor, Grant\/Contract. <br><b>Aglea, Agios, Apollomics, Astellas, BIND Therapeutics, Calithera Biosciences, Celldex, Clovis Oncology, cyteir, Daiichi Sankyo, Eisai, Elevation Oncology, G1 Therapeutics, GRAIL, ImClone Systems<\/b> Grant\/Contract. <br><b>Celgene<\/b> Independent Contractor, Grant\/Contract. <br><b>Immunogen, Ipsen, Janssen Oncology, Lilly, MedImmune, Neon Therapeutics, Tesaro, Transgene, UT Southwestern Medical Center - Simmons Cancer Center<\/b> Grant\/Contract.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11481","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"15","PosterboardNumber":"19","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT191","PresenterBiography":null,"PresenterDisplayName":"Allyson Hamlin, PhD","PresenterKey":"d1d3d2d7-6119-4fdc-9b78-f59abcb719b9","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT191. First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed\/refractory advanced solid tumors: Interim data","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed\/refractory advanced solid tumors: Interim data","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Immunotherapy,Cancer,CD40,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Y. Ba<\/b><sup>1<\/sup>, H. Zhang<sup>2<\/sup>, T. Deng<sup>3<\/sup>, T. Ning<sup>3<\/sup>, Q. Fan<sup>2<\/sup>; <br\/><sup>1<\/sup>Department of GI Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.  Department of Cancer Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China, <sup>2<\/sup>Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, <sup>3<\/sup>Department of GI Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China","CSlideId":"","ControlKey":"76d7fc8a-0bce-401d-9786-54bacd2393e4","ControlNumber":"10267","DisclosureBlock":"&nbsp;<b>Y. Ba, <\/b> None..<br><b>H. Zhang, <\/b> None..<br><b>T. Deng, <\/b> None..<br><b>T. Ning, <\/b> None..<br><b>Q. Fan, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11482","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"16","PosterboardNumber":"20","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT192","PresenterBiography":null,"PresenterDisplayName":"Yi Ba","PresenterKey":"9c91002f-e3cd-4125-808d-e4faed6cbbe4","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT192. A first-in-human phase 1 study of TQB2916, a novel CD40 agonist antibody for advanced malignancies","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A first-in-human phase 1 study of TQB2916, a novel CD40 agonist antibody for advanced malignancies","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Anticancer therapy,Vaccines,T cell engager,Hsp90,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"E. Kang<sup>1<\/sup>, K. Lee<sup>1<\/sup>, I. Kim<sup>2<\/sup>, J. Kim<sup>3<\/sup>, J. Kim<sup>3<\/sup>, S. Lee<sup>3<\/sup>, J. Lee<sup>3<\/sup>, K. Shin<sup>2<\/sup>, S. Park<sup>2<\/sup>, J. Kim<sup>2<\/sup>, H. Shin<sup>4<\/sup>, <b>K. Park<\/b><sup>3<\/sup>; <br\/><sup>1<\/sup>Korea University Guro Hospital, Seoul, Korea, Republic of, <sup>2<\/sup>Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea, Republic of, <sup>3<\/sup>Korea University Anam Hospital, Seoul, Korea, Republic of, <sup>4<\/sup>Aston Sci. Inc., Seoul, Korea, Republic of","CSlideId":"","ControlKey":"4c2804b0-4789-4464-b226-1ff8516bcfb2","ControlNumber":"10403","DisclosureBlock":"&nbsp;<b>E. Kang, <\/b> None..<br><b>K. Lee, <\/b> None..<br><b>I. Kim, <\/b> None..<br><b>J. Kim, <\/b> None..<br><b>J. Kim, <\/b> None..<br><b>S. Lee, <\/b> None..<br><b>J. Lee, <\/b> None..<br><b>K. Shin, <\/b> None..<br><b>S. Park, <\/b> None..<br><b>J. Kim, <\/b> None..<br><b>H. Shin, <\/b> None..<br><b>K. Park, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11483","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"17","PosterboardNumber":"21","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT193","PresenterBiography":null,"PresenterDisplayName":"Kyong Hwa Park, MD, PhD","PresenterKey":"7cd50bb5-d5b7-4b5b-ae44-1aa159bb2a04","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT193. Phase 1 clinical trial evaluating the safety, tolerability, and immunogenicity of AST-021p, a novel cancer vaccine targeting HSP90-derived epitopes in advanced solid tumor patients (CornerStone-002)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 1 clinical trial evaluating the safety, tolerability, and immunogenicity of AST-021p, a novel cancer vaccine targeting HSP90-derived epitopes in advanced solid tumor patients (CornerStone-002)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Phase I,Small molecule drugs,Cell signaling,Mitochondria,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>L. G. Berthiaume<\/b><sup>1<\/sup>, E. Beauchamp<sup>2<\/sup>, J. Gamma<sup>1<\/sup>, R. Pain<sup>1<\/sup>, M. A. Kostiuk<sup>1<\/sup>, C. R. Cromwell<sup>1<\/sup>, E. W. Moussa<sup>1<\/sup>, O. Julien<sup>1<\/sup>, B. P. Hubbard<sup>1<\/sup>, J. Kuruvilla<sup>3<\/sup>, L. H. Sehn<sup>4<\/sup>, J. Spratlin<sup>5<\/sup>, R. Jamal<sup>6<\/sup>, R. Sangha<sup>5<\/sup>, J. R. Mackey<sup>2<\/sup>; <br\/><sup>1<\/sup>University of Alberta, Edmonton, AB, Canada, <sup>2<\/sup>Pacylex Pharmaceuticals Inc, Edmonton, AB, Canada, <sup>3<\/sup>Princess Margaret Cancer Centre, Toronto, ON, Canada, <sup>4<\/sup>University of British Colombia, Vancouver, BC, Canada, <sup>5<\/sup>Cross Cancer Institute, Edmonton, AB, Canada, <sup>6<\/sup>Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada","CSlideId":"","ControlKey":"3be05306-625c-4557-86b8-b9d4c8e9214a","ControlNumber":"10316","DisclosureBlock":"<b>&nbsp;L. G. Berthiaume, <\/b> <br><b>Pacylex Pharmaceuticals Inc<\/b> Independent Contractor, Stock, Stock Option, Patent. <br><b>Eusera<\/b> Stock, Sole owner. <br><b>E. Beauchamp, <\/b> <br><b>Pacylex Pharmaceuticals Inc<\/b> Employment, Stock, Stock Option, Patent. <br><b>J. Gamma, <\/b> <br><b>Pacylex Pharmaceuticals Inc<\/b> Stock, Patent. <br><b>R. Pain, <\/b> <br><b>Pacylex Pharmaceuticals Inc<\/b> Stock.<br><b>M. A. Kostiuk, <\/b> None..<br><b>C. R. Cromwell, <\/b> None..<br><b>E. W. Moussa, <\/b> None..<br><b>O. Julien, <\/b> None..<br><b>B. P. Hubbard, <\/b> None..<br><b>J. Kuruvilla, <\/b> None..<br><b>L. H. Sehn, <\/b> None..<br><b>J. Spratlin, <\/b> None..<br><b>R. Jamal, <\/b> None..<br><b>R. Sangha, <\/b> None.&nbsp;<br><b>J. R. Mackey, <\/b> <br><b>Pacylex Pharmaceuticals Inc<\/b> Employment, Stock, Stock Option.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11484","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"18","PosterboardNumber":"22","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT194","PresenterBiography":null,"PresenterDisplayName":"Luc Berthiaume, PhD","PresenterKey":"b323f592-38d5-432f-9956-a42f9b707398","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT194. N-myristoylation inhibitor zelenirstat: New mechanistic insights and efficacy signals from a first in human phase I study","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"N-myristoylation inhibitor zelenirstat: New mechanistic insights and efficacy signals from a first in human phase I study","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"WEE1,DNA damage response,Solid tumors,CCNE1 amplification,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"T. A. Yap<sup>1<\/sup>, C. Miller<sup>2<\/sup>, D. Stenehjem<sup>3<\/sup>, E. J. Brown<sup>4<\/sup>, M. Carleton<sup>2<\/sup>, <b>N. Q. Mirza<\/b><sup>2<\/sup>; <br\/><sup>1<\/sup>The University of Texas MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>Aprea Therapeutics, Inc., Doylestown, PA, <sup>3<\/sup>University of Minnesota, Duluth, MN, <sup>4<\/sup>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA","CSlideId":"","ControlKey":"32e4a55f-c6aa-451c-bae5-f661d980f1db","ControlNumber":"10255","DisclosureBlock":"<b>&nbsp;T. A. Yap, <\/b> <br><b>AbbVie, Acrivon, Adagene, Almac, Aduro, Amphista, Artios, Astex, AstraZeneca, Athena, Atrin, Avenzo, Avoro, Axiom, Baptist Health Systems, Bayer, Beigene, BioCity Pharma, Blueprint, Boxer<\/b> Other, Consultant. <br><b>Bristol Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Carrick Therapeutics, Circle Pharma, Clovis, Cybrexa, Daiichi Sankyo, Dark Blue Therapeutics, Diffusion, Duke Street Bio<\/b> Consultant. <br><b>858 Therapeutics, EcoR1 Capital, Ellipses Pharma, EMD Serono, Entos, F-Star, Genesis Therapeutics, Genmab, Glenmark, GLG, Globe Life Sciences, GSK, Guidepoint, Ideaya Biosciences, Idience, Ignyta<\/b> Other, Consultant. <br><b>I-Mab, ImmuneSensor, Impact Therapeutics, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI pharma, Mereo, Merck, Merit, Monte Rosa Therapeutics, Natera, Nested Therapeutics, Nexys, Nimbus<\/b> Other, Consultant. <br><b>Novocure, Odyssey, OHSU, OncoSec, Ono Pharma, Onxeo, PanAngium Therapeutics, Pegascy, PER, Pfizer, Piper-Sandler, Pliant Therapeutics, Prolynx, Protai Bio, Radiopharma Theranostics, Repare, resTORbio<\/b> Other, Consultant. <br><b>Roche, Ryvu Therapeutics, SAKK, Sanofi, Schrodinger, Servier, Synnovation, Synthis Therapeutics, Tango, TCG Crossover, TD2, Terremoto Biosciences, Tessellate Bio, Theragnostics, Terns Pharmaceuticals<\/b> Other, Consultant. <br><b>Tolremo, Tome, Thryv Therapeutics, Trevarx Biomedical, Varian, Veeva, Versant, Vibliome, Voronoi Inc, Xinthera, Zai Labs and ZielBio<\/b> Other, Consultant. <br><b>Acrivon, Artios, AstraZeneca, Bayer, Beigene, BioNTech, Blueprint, BMS, Boundless Bio, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, Haihe<\/b> Other, Grant\/Research support. <br><b>Ideaya ImmuneSensor, Insilico Medicine, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Rubius, Sanofi, Scholar Rock<\/b> Other, Grant\/Research support. <br><b>Seattle Genetics, Tango, Tesaro, Vivace and Zenith<\/b> Other, Grant\/Research support. <br><b>Seagen<\/b> Stock. <br><b>C. Miller, <\/b> <br><b>Aprea Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>D. Stenehjem, <\/b> <br><b>Aprea, Salarius, Iterion, Dracen, Mirati, BMS, SonALAsense, MTEM<\/b> Independent Contractor. <br><b>BMS, Novartis, Bayer, Springworks, Grail, AstraZenca<\/b> Grant\/Contract. <br><b>E. J. Brown, <\/b> <br><b>Aprea Therapeutics, Inc<\/b> Independent Contractor, Stock, Stock Option, Grant\/Contract, Travel, Patent. <br><b>BreakSight, Inc.<\/b> Stock Option. <br><b>M. Carleton, <\/b> <br><b>Aprea Therapeutics, Inc.<\/b> Independent Contractor, Stock Option. <br><b>N. Q. Mirza, <\/b> <br><b>Aprea Therapeutics, Inc<\/b> Independent Contractor, Stock Option, Travel.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11485","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"19","PosterboardNumber":"23","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT195","PresenterBiography":null,"PresenterDisplayName":"Nadeem Mirza, MD;MPH","PresenterKey":"d746e01a-cf91-4899-bf2a-de16dda53d2b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT195. First-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors harboring cancer-associated gene alterations","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"First-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors harboring cancer-associated gene alterations","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"ATR,DNA damage response,Solid tumors,Macrocyclic,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"F. Simpkins<sup>1<\/sup>, A. Mahipal<sup>2<\/sup>, P. LoRusso<sup>3<\/sup>, R. Schneider<sup>4<\/sup>, C. Miller<sup>5<\/sup>, D. Stenehjem<sup>6<\/sup>, E. J. Brown<sup>7<\/sup>, M. Carleton<sup>5<\/sup>, J. Gullbo<sup>8<\/sup>, <b>N. Q. Mirza<\/b><sup>5<\/sup>; <br\/><sup>1<\/sup>Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, <sup>2<\/sup>University Hospital Cleveland Medical Center, Cleveland, OH, <sup>3<\/sup>Yale Cancer Center, New Haven, CT, <sup>4<\/sup>Mary Crowley Cancer Research Center, Dallas, TX, <sup>5<\/sup>Aprea Therapeutics, Inc., Doylestown, PA, <sup>6<\/sup>University of Minnesota, Duluth, MN, <sup>7<\/sup>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, <sup>8<\/sup>Theradex Oncology, Princeton, NJ","CSlideId":"","ControlKey":"8cf08c64-ee4b-4ff4-b405-519232e1cb5f","ControlNumber":"10335","DisclosureBlock":"<b>&nbsp;F. Simpkins, <\/b> <br><b>AstraZeneca, GSK and Zentalis Pharmaceuticals<\/b> Other, Scientific advisory board. <br><b>AstraZeneca, Repare Therapeutics, Instill Bio and Sierra Oncology<\/b> Other, Institutional research funding. <br><b>A. Mahipal, <\/b> <br><b>Exelixis, AstraZeneca, Merck, Taiho Oncology<\/b> Other, Advisory Board. <br><b>AstraZeneca, Exelixis<\/b> Other, Speakers bureau. <br><b>P. LoRusso, <\/b> <br><b>AbbVie, Takeda, Agenus, IQVIA, Pfizer, Glaxo-Smith Kline, QED Therapeutics, AstraZeneca, EMD Serono, Kyowa Kirin Pharmaceutical Development, Kineta, Inc., Zentalis Pharmaceuticals<\/b> Other, Advisory board. <br><b>Molecular Templates, ABL Bio, STCube Pharmaceuticals, I-Mab, Seagen, imCheck, Relay Therapeutics, Stemline, Compass BADX, Mekanistic, Mersana Therapeutics, BAKX Therapeutics, Scenic Biotech<\/b> Other, Advisory board. <br><b>Qualigen, NeuroTrials, Actuate Therapeutics, Atreca Development, Cullinan, Quanta Therapeutics, Schrodinger, Boehrigner Ingelheim<\/b> Other, Advisory board. <br><b>Roche-Genentech<\/b> imCORE Alliance. <br><b>SOTIO, I-Mab, Roivant Sciences,  Amgen CodeBreak 202<\/b> Other, Consultant. <br><b>SOTIO, Amgen CodeBreak 202, DrenBioData Safety Monitoring Board<\/b> Other, Data Safety Monitoring Board.<br><b>R. Schneider, <\/b> None.&nbsp;<br><b>C. Miller, <\/b> <br><b>Aprea Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>D. Stenehjem, <\/b> <br><b>Aprea, Salarius, Iterion, Dracen, Mirati, BMS, SonALAsense, MTEM<\/b> Independent Contractor. <br><b>BMS, Novartis, Bayer, Springworks, Grail, AstraZenca<\/b> Grant\/Contract. <br><b>E. J. Brown, <\/b> <br><b>Aprea Therapeutics, Inc.<\/b> Independent Contractor, Stock, Stock Option, Grant\/Contract, Travel, Patent. <br><b>BreakSight, Inc.<\/b> Stock Option. <br><b>M. Carleton, <\/b> <br><b>Aprea Therapeutics, Inc.<\/b> Independent Contractor, Stock Option.<br><b>J. Gullbo, <\/b> None.&nbsp;<br><b>N. Q. Mirza, <\/b> <br><b>Aprea Therapeutics, Inc.<\/b> Independent Contractor, Stock Option, Travel.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11486","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"20","PosterboardNumber":"24","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT196","PresenterBiography":null,"PresenterDisplayName":"Nadeem Mirza, MD;MPH","PresenterKey":"d746e01a-cf91-4899-bf2a-de16dda53d2b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT196. First-in-human phase 1\/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"611","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"First-in-human phase 1\/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors","Topics":null,"cSlideId":""}]